95
Participants
Start Date
June 26, 2025
Primary Completion Date
June 30, 2028
Study Completion Date
June 30, 2028
Determine the ED50 and ED95 of esketamine
According to Dixon's up-and-down sequential design, esketamine will be initiated at 0.3 mg∙kg-1 intravenously, followed by dose adjustments (0.02 mg∙kg-1 increments/decrements) based on somatic responses to cervical dilation (positive: any movement; negative: no movement). The tests will continued until six crossover pairs are achieved.
Intravenous the dose of esketamine ED95
The intervention group will be injected with the dose of esketamine ED95.
Intravenous remifentanil 1μg∙kg-1
The control group will be injected with remifentanil 1μg∙kg-1.
Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, China, Xiamen
The First Affiliated Hospital of Xiamen University
OTHER